Status:
RECRUITING
Systemic Therapy With a Loco-regional Treatment in Patients With Locally Advanced Pancreatic Cancer
Lead Sponsor:
University of Saskatchewan
Conditions:
Locally Advanced Pancreatic Cancer
Irreversible Electroporation
Eligibility:
All Genders
Phase:
NA
Brief Summary
Background Pancreatic cancer is one the leading causes of cancer-related death in Canada. Approximately 40 percent of patients with pancreatic cancer present with locally advanced pancreatic cancer a...
Detailed Description
Current Knowledge and Rationale Pancreatic cancer is one of the most lethal malignancies, with an overall 5-year survival rate of less than 10%. It is the 12th most common cancer and 7th most frequen...
Eligibility Criteria
Inclusion
- Adult patients with biopsy-proven locally advanced pancreatic adenocarcinoma who are candidates for combination chemotherapy as determined by treating oncologists.
Exclusion
- Pregnancy
- Metastatic pancreatic cancer
- Another active second primary cancer with the exception of squamous cell carcinoma of the skin or an in situ cancer.
Key Trial Info
Start Date :
May 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT04276857
Start Date
May 1 2025
End Date
December 31 2026
Last Update
May 13 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Allan Blair Cancer Center
Regina, Saskatchewan, Canada
2
Saskatoon Cancer Center
Saskatoon, Saskatchewan, Canada, S7N4H4